US Patent
US8999996 — Hydrazide containing nuclear transport modulators and uses thereof
Composition of Matter · Assigned to Karyopharm Therapeutics Inc · Expires 2033-07-03 · 7y remaining
Vulnerability score
17/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a compound represented by structural formula I and its pharmaceutically acceptable salts, used as nuclear transport modulators.
USPTO Abstract
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.